Veracyte (VCYT) Competitors $35.10 +0.49 (+1.42%) Closing price 04:00 PM EasternExtended Trading$35.22 +0.12 (+0.34%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, RDNT, BTSG, SHC, OPCH, and WGSShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Option Care Health (OPCH), and GeneDx (WGS). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics RadNet BrightSpring Health Services Sotera Health Option Care Health GeneDx Veracyte (NASDAQ:VCYT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Which has higher valuation & earnings, VCYT or ADPT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$445.76M6.19$24.14M$0.33106.36Adaptive Biotechnologies$178.96M13.23-$159.49M-$0.82-18.96 Do analysts rate VCYT or ADPT? Veracyte presently has a consensus price target of $40.90, indicating a potential upside of 16.52%. Adaptive Biotechnologies has a consensus price target of $13.22, indicating a potential downside of 14.97%. Given Veracyte's higher possible upside, research analysts clearly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 2 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.67Adaptive Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is VCYT or ADPT more profitable? Veracyte has a net margin of 5.50% compared to Adaptive Biotechnologies' net margin of -59.07%. Veracyte's return on equity of 6.07% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Veracyte5.50% 6.07% 5.53% Adaptive Biotechnologies -59.07%-60.93%-23.03% Does the media prefer VCYT or ADPT? In the previous week, Veracyte had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Veracyte and 6 mentions for Adaptive Biotechnologies. Veracyte's average media sentiment score of 0.71 beat Adaptive Biotechnologies' score of 0.46 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, VCYT or ADPT? Veracyte has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Do institutionals & insiders have more ownership in VCYT or ADPT? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryVeracyte beats Adaptive Biotechnologies on 12 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.76B$6.97B$6.10B$10.65BDividend YieldN/A1.15%5.70%4.74%P/E Ratio106.3727.6685.5527.59Price / Sales6.19198.81622.26138.47Price / Cash34.7622.0037.7861.77Price / Book2.315.4513.136.76Net Income$24.14M$178.04M$3.30B$275.88M7 Day Performance-3.07%5.08%5.29%3.72%1 Month Performance8.13%12.65%9.94%10.22%1 Year Performance4.84%35.38%87.78%35.86% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.8043 of 5 stars$35.10+1.4%$40.90+16.5%+2.2%$2.76B$445.76M106.37790News CoverageAnalyst UpgradeInsider TradeADPTAdaptive Biotechnologies3.0574 of 5 stars$13.46+1.8%$12.38-8.1%+165.2%$2.01B$178.96M-16.41790Analyst ForecastBEAMBeam Therapeutics2.9226 of 5 stars$23.91+4.1%$46.40+94.1%+7.4%$2.32B$63.52M-5.31510News CoveragePositive NewsAnalyst ForecastGHGuardant Health3.5719 of 5 stars$61.99+3.3%$65.25+5.3%+197.1%$7.49B$739.02M-18.502,021Analyst ForecastTWSTTwist Bioscience3.7678 of 5 stars$27.00+0.3%$49.40+83.0%-26.2%$1.62B$312.97M-18.62990Analyst ForecastTXG10x Genomics3.8865 of 5 stars$11.34-3.2%$13.65+20.4%-41.5%$1.46B$610.78M-16.201,240High Trading VolumeRDNTRadNet3.1283 of 5 stars$74.70-1.6%$76.80+2.8%+16.4%$5.84B$1.83B-373.4811,021Positive NewsAnalyst ForecastBTSGBrightSpring Health Services2.9179 of 5 stars$28.13+2.7%$27.10-3.7%+94.8%$4.85B$12.57B90.7435,000Analyst ForecastSHCSotera Health2.682 of 5 stars$15.75-0.4%$16.00+1.6%+4.0%$4.49B$1.10B196.903,000Analyst ForecastOPCHOption Care Health4.8751 of 5 stars$27.54+0.9%$35.75+29.8%-4.5%$4.43B$5.00B22.038,088Positive NewsAnalyst ForecastWGSGeneDx2.3205 of 5 stars$113.93-2.8%$104.13-8.6%+128.9%$3.37B$362.32M2,278.601,200Analyst Forecast Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Option Care Health Competitors GeneDx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
